Day One Biopharmaceuticals, Inc. (DAWN) is a Biotechnology company in the Healthcare sector, currently trading at $21.46. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is DAWN = $24 (+10.7% upside).
Valuation: DAWN trades at a trailing Price-to-Earnings (P/E) of -20.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.27.
Financials: revenue is $158M, +20.6%/yr average growth. Net income is $107M (loss), growing at -2%/yr. Net profit margin is -67.8% (negative). Gross margin is 89.1% (-6.9 pp trend).
Balance sheet: total debt is $3M against $441M equity (Debt-to-Equity (D/E) ratio 0.01, conservative). Current ratio is 8.02 (strong liquidity). Debt-to-assets is 0.5%. Total assets: $508M.
Analyst outlook: 6 / 12 analysts rate DAWN as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 83/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 55/100 (Partial), Future 52/100 (Partial), Income 10/100 (Fail).
